Psychiatry

A large portion of communication is non-verbal.

Clinicians rated 82% of the patients receiving the study drug and 46% in the placebo group as either much improved or very much improved on the Clinical Global Impression of Improvement scale.

Attempts to use neuroimaging to screen for ADHD in the past have failed.

Both methylphenidate PRC-063 and lisdexamfetamine led to improved performances for drivers with ADHD.

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.

Precision medicine could have a major impact in ADHD.

ADHD is associated with increased procedures, including blood transfusions, hospital admissions, and emergency department visits.

Screenings for ADHD have not improved in several years.

Medications in psychiatry are often ineffective for patients.

Only 29.5% of sampled CBD users claimed any wellness benefit.

Dr. Cortese discusses how new research can drive changes to ADHD clinical trials.

The younger generation is able to adapt to new technology for therapy better than previous generations.

Cataracts, but not AMD or glaucoma, were associated with an increased risk of depressive symptoms in the elderly in a prospective long-term study.

The schizophrenia drug currently has a PDUFA date set for November 15.

The Arbor Pharmaceutical drug is aimed at treating ADHD without being manipulated for non-oral use.

ELP Pharma readying plans to continue to study the drug in a phase 3 trial.

There was also a decline depression care in recent years among adolescents and young adults.

A virtual reality platform could enable ADHD patients to improve cognitive functioning.

Paul Christo, MD, discusses opioid addiction during the pandemic, the role of the clinician, and offers a hopeful outlook for the future.

Experts expect an increase in mental health issues caused by the pandemic in the future.

Medication might be best used as a first-line option for patients with ADHD.

An expert discusses trends in pediatric mental health and receipt of treatment.

Higher levels of acetaminophen detected in meconium was linked to increased odds of developing ADHD by 6-7 years old.

There could be a lasting impact caused by some of the changes due to the pandemic.

This edition from the 10 Year Plan features perspective from leadership at APA and AADPRT, as well as survey results from psychiatrists.